Ifosfamide alone and in combination in the treatment of refractory malignant gestational trophoblastic disease.
OBJECTIVE
We attempted to evaluate the use of ifosfamide either alone or in combination in patients with refractory malignant gestational trophoblastic disease.


METHODS
Our study comprised, in part, a phase II multiinstitutional trial of ifosfamide in refractory gynecologic malignancies and, in part, a review of institutional experience with ifosfamide in combination chemotherapy.


RESULTS
Single-agent ifosfamide produced a significant response in titer in one of two patients with refractory choriocarcinoma. Ifosfamide with etoposide and cisplatin (also known as VIP) resulted in significant response in human chorionic gonadotropin titers in three patients with highly refractory metastatic gestational trophoblastic disease and one cure in this group of patients.


CONCLUSIONS
Ifosfamide has activity in refractory choriocarcinoma and, when combined with etoposide and cisplatin (VIP), may be curative.
Sutton
G P
GP
Department of Obstetrics and Gynecology, Indiana University Medical School, Indianapolis.
Soper
J T
JT
Blessing
J A
JA
Hatch
K D
KD
Barnhill
D R
DR
D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002822:Choriocarcinoma / Q000188:drug therapy* / Q000556:secondary; D002945:Cisplatin / Q000627:therapeutic use; D005047:Etoposide / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage / Q000627:therapeutic use*; D008875:Middle Aged; D011247:Pregnancy; D011252:Pregnancy Complications, Neoplastic; D014328:Trophoblastic Neoplasms / Q000188:drug therapy* / Q000556:secondary
D005047:Etoposide; D002945:Cisplatin; D007069:Ifosfamide